SOUTH SAN FRANCISCO, Calif., May 13, 2022 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2022 and provided a corporate update.
“The team continued to execute well throughout the first quarter of this year, enabling us to present the first clinical data from a Tempest program at the ASCO Annual Meeting in June,” said Stephen R. Brady, chief executive officer of Tempest. “We look forward to the upcoming oral presentation, which will highlight the clinical profile and responses observed in the monotherapy and combination Phase 1 study of TPST-1120, our novel PPARa antagonist.”
________________________
1 If approved by the FDA
Recent Highlights
Planned Near-Term Milestones
PIPE Financing
Financial Results
First Quarter
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both TPST-1120 and TPST-1495 are advancing through Phase 1 clinical trials designed to study both agents as monotherapies and in combination with other approved agents. In collaboration with F. Hoffmann La Roche, TPST-1120 is also advancing in a randomized, global, Phase 1b/2 clinical study in combination with the standard-of-care regimen of atezolizumab and bevacizumab in the first-line treatment of patients with advanced or metastatic hepatocellular carcinoma. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”)) concerning Tempest Therapeutics, Inc. (“Tempest Therapeutics”). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. All statements that are not historical facts are forward-looking statements, including any statements regarding the timing and selection of development candidates, dose selection or commencement of, or availability of data from, clinical trials, the company’s guidance regarding cash resources, as well as our operational plans and the timing and ability to deliver on value-creating milestones. Forward-looking statements are based on information available to Tempest Therapeutics as of the date hereof and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. These and other risks are described in greater detail in the Form 10-K filed by Tempest Therapeutics with the Securities and Exchange Commission on March 29, 2022. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics’ views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics.
TEMPEST THERAPEUTICS, INC. | |||||||
Consolidated Balance Sheets | |||||||
(in thousands) | |||||||
March 31, 2022 | December 31, 2021 | ||||||
Assets | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 45,754 | $ | 51,829 | |||
Insurance recovery of legal settlement | 15,000 | 15,000 | |||||
Prepaid expenses and other current assets | 1,956 | 2,134 | |||||
Total current assets | 62,710 | 68,963 | |||||
Property and equipment, net | 1,024 | 1,113 | |||||
Operating lease right-of-use assets | 2,739 | 3,051 | |||||
Other noncurrent assets | 480 | 111 | |||||
Total assets | $ | 66,953 | $ | 73,238 | |||
Liabilities and Stockholders’ Equity (Deficit) | |||||||
Current liabilities | |||||||
Accounts payable | $ | 684 | $ | 991 | |||
Accrued legal settlement | 15,000 | 15,000 | |||||
Accrued expenses and other | 3,564 | 2,501 | |||||
Current operating lease liabilities | 1,473 | 1,442 | |||||
Interest payable | 94 | 92 | |||||
Total current liabilities | 20,815 | 20,026 | |||||
Loan payable, net | 15,133 | 15,069 | |||||
Operating lease liabilities | 1,648 | 2,026 | |||||
Total liabilities | 37,596 | 37,121 | |||||
Stockholders’ equity (deficit) | |||||||
Common stock | 7 | 7 | |||||
Additional paid-in capital | 137,904 | 136,173 | |||||
Accumulated deficit | (108,554 | ) | (100,063 | ) | |||
Total stockholders’ equity (deficit) | 29,357 | 36,117 | |||||
Total liabilities and stockholders’ equity (deficit) | $ | 66,953 | $ | 73,238 | |||
TEMPEST THERAPEUTICS, INC. | |||||||
Consolidated Statements of Operations | |||||||
(in thousands except per share amounts) | |||||||
Three months ended | Three months ended | ||||||
March 31, 2022 | March 31, 2021 | ||||||
Expenses: | |||||||
Research and development | $ | 5,109 | $ | 3,592 | |||
General and administrative | 3,052 | 1,535 | |||||
Total expenses | 8,161 | 5,127 | |||||
Operating loss | (8,161 | ) | (5,127 | ) | |||
Other income (expense), net: | |||||||
Interest expense | (333 | ) | (231 | ) | |||
Interest and other income, net | 3 | 3 | |||||
Net loss | $ | (8,491 | ) | $ | (5,355 | ) | |
Net loss per share | $ | (1.18 | ) | $ | (10.55 | ) | |
Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
FORT WORTH, Texas, Dec. 24, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) today announced…
- Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be…
If you are male and in your 40's and 50's and feel your testosterone levels…
Transforming Anxiety into Positive Energy: A New Approach by The Anxiety ClinicBondi Junction, New South…
Embracing Mental Well-Being During the Festive SeasonCarlton North, Australia--(Newsfile Corp. - December 24, 2024) -…
If you are researching the strongest over the counter weight loss supplements in 2025 -…